XNAS · Healthcare · Biotechnology
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.30 | -0.34 | -13.33% | $0 | ❌ Miss | -3.42% | -12.82% | — |
| 2026-05-14 | Q1 2026 | -0.28 | -0.50 | -80.00% | $0 | ❌ Miss | -2.87% | -13.40% | -39.71% |
| 2026-03-30 |
| Q4 2025 |
| -0.62 |
| -0.62 |
| +0.00% |
| $0 |
| ➖ Inline |
| +1.16% |
| +4.61% |
| +14.47% |
| 2025-11-05 | Q3 2025 | -3.27 | -0.79 | +75.84% | $0 | ✅ Beat | — | — | — |
| 2025-08-11 | Q2 2025 | -2.88 | -2.07 | +28.12% | $0 | ✅ Beat | -4.87% | +26.84% | +31.15% |
| 2025-03-27 | Q4 2024 | -0.25 | -0.39 | -56.00% | $0 | ❌ Miss | -8.07% | -14.45% | -28.30% |
| 2024-03-19 | Q4 2023 | -0.39 | -0.34 | +12.82% | $0 | ✅ Beat | — | — | — |
| 2023-11-08 | Q3 2023 | -0.57 | -0.48 | +15.79% | $0 | ✅ Beat | +16.31% | +17.02% | +13.48% |
Showing last 8 quarters.